Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-04-07
1997-07-08
Schain, Howard E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530303, 530311, 530399, A61K 1400, A61K 3827, A61K 3814
Patent
active
056461135
ABSTRACT:
Methods for increasing the growth rate of a human patient having partial growth hormone insensitivity syndrome, but not Laron syndrome, are described. One such method comprises administering a dose of greater than 0.3 mg/kg/week of growth hormone, preferably growth hormone with a native human sequence, with or without an N-terminal methionine, to the patient. The patient is characterized as having a height of less than about -2 standard deviations below normal for age and sex, serum levels of high-affinity growth hormone binding protein and IGF-I that are at least 2 standard deviations below normal levels, and a serum level of growth hormone that is at least normal. In another such method, the same patient population is treated with an effective amount of IGF-I alone or in combination with an amount of growth hormone that is effective in combination with IGF-I.
REFERENCES:
patent: 5126324 (1992-06-01), Clark et al.
Rosenfeld et al., "Growth Hormone (GH) Insensitivity" Receptor Deficiency, Endocrine Reviews 15 (3):369-90 (1994).
Aguirre et al., "High-Affinity Serum Growth-Hormone-Binding Protein, Absent in Laron-Type Dwarfism, is Diminished in Heterozygous Parents" Horm. Res. 34:4-8 (1990).
Amselem et al., "Spectrum of Growth Hormone Receptor Mutations and Associated Haplotypes in Laron Syndrome" Hormone Molecular Genetics 2 (4) :355-359 (1993).
August et al., "Growth Hormone Treatment in the United States: Demographic and Diagnostic Features of 2331 Children" J. Pediatr. 116 (6) :899-903 (1990).
Blum et al., "Improvement of Diagnostic Criteria in Growth Hormone Insensitivity Syndrome: Solutions and Pitfalls" Acta Paediatr. Suppl., B. Lippe et al., Lisbon, Portugal vol. 399:117-124 (Presented Oct. 1993).
Carlsson et al., "Reduced Concentration of Serum Growth Hormone-Binding Protein in Children with Idiopathic Short Stature" J. Clin. Endocrinol. and Metab. 78 (6) :1325-1330 (1994).
Eshet et al., "Defect of Human Growth Hormone Receptors in the Liver of Two Patients with Laron-Type Dwarfism" Is. J. Med. Sci. 20:8-11 (1984).
Fine et al., "Growth After Recombinant Human Growth Hormone Treatment in Children with Chronic Renal Failure: Report of a Multicenter Randomized Double-Blind Placebo-Controlled Study" J. Pediat. 1241(3) :374-382 (March 1994).
Gillespie et al., "Enhanced Potency of Truncated Insulin-Like Growth Factor-I (des (1-3) IGF-I) Relative to IGF-I in lit/lit mice" J. Endocrinol. 127:401-405 (1990).
Goddard et al., "Growth Hormone (GH) Receptor Defects are Present in Selected Children with Non-GH-Deficient Short Stature: A Molecular Basis for Partial GH-Insensitivity" Proc. 76th Ann. Meeting of Endocrine Soc. pp. 204 (Jun. 1994).
Hayek et al., "Growth and Somatomedin-C Responses to Growth Hormone in Dwarfed Children" J. Pediatrics 99 (6) :868-872 (1981).
Kou et al., "Amino Acid Substitutions in the Intraceullular Part of the Growth Hormone Receptor in a Patient with Laron Syndrome " J. Clin. Endocrino. and Metab. 76:54-59 (1993).
Kowarski et al., "Growth Failure with Normal Serum RIA-GH and Low Somatomedin Activity: Somatomedin Restoration and Growth Acceleration After Exogenous GH" J. Clin. Endocrinol. and Metab. 47 (2) :461-464 (1978).
Laron et al., "Serum GH Binding Protein Activities Identifies the Heterozygous Carriers for Laron Type Dwarfism" Acta Endocrinologica 121 :603-608 (1989).
Martin et al., "Effects of Insulin-Like Growth Factor-I Peptides in Rats with Acute Renal Failure" J. Endocrinol. 140:23-32 (1994).
Martin et al., "IGF-I and its Variant, des-(1-3) IGF-I, Enhance Growth in Rats with Reduced Renal Mass" Am. J. Physiol. 261:F626-633 (1991).
Martin et al., "Insulin-Like Growth Factor I and its Variant, Des(1-3)IGF-I, Improve Nitrogen Balance and Food Utilization in Rats with Renal Failure" Miner. Electrolyte Metab. 18:264-268 (1992).
Mauras et al., "Growth Hormone-Binding Protein Levels: Studies of Children with Short Stature" Metabolism 43 (3) :357-359 (1994).
Pharmacia, "IGF-I: Wide-Ranging Benefits" GH Insensitivity Syndromes, England:Oxford Clinical Communications (Oct. 1993).
Read et al., "Insulin-Like Growth Factor-I and its N-terminal Modified Analogues Induce Marked Gut Growth in Dexamethasone-Treated Rats" J. Endocrinol, 133:421-431 (1992).
Rose et al., "The Advantage of Measuring Stimulated as Compared with Spontaneous Growth Hormone Levels in the Diagnosis of Growth Hormone Deficiency" New England J. of Medicine 319:201-207 (1988).
Rosenbloom et al., "Is There Heterozygote Expression of Growth Hormone Receptor Deficiency?" Acta Paediatr. Suppl. 399:125-127 (1994).
Rosenfeld et al.,"Growth Hormone (GH) Insensittivity Due to Primary GH Receptor Deficiency" Endocrine Reviews 15 (3) :369-390 (1994).
Tomas et al., "Anabolic Effects of Insulin-Like Growth Factor-I (IGF-I) and an IGF-I Variant in Normal Female Rats" J. Endocrinol, 137:413-421 (1993).
Tomas et al., "Insulin-Like Growth Factor-I and more Potent Variants Restore Growth of Diabetic Rats Without Inducing All Characteristic Insulin Effects" Biochemistry 291:781-786 (1993).
v. Kalckreuth, "Constitutional Delay of Growth and Puberty: Do They Really Reach Their Target Height?" Horm. Res. 35:222-225 (1991).
Valenta et al., "Pituitary Dwarfism in a Patient with Circulating Abnormal Growth Hormone Polymers" New England J. of Medicine 312:214-217 (1985).
Albertsson-Wikland, "Growth Hormone Treatment in Short Children-Short-Term and Long-Term Effects on Growth", Acta Paediatr Scand (Suppl), 343:77-84 (1988).
Albertsson-Wikland et al., "Analyses of 24-Hour Growth Hormone Profiles in Children: Relation to Growth", Journal of Clinical Endocrinology and Metabolism, 67(3):493-500 (1988).
Amselem et al., "Molecular Basis of Laron Dwarfism", TEM--Elsevier Science Publishing Co., Inc., pp. 35-40, (1991).
Amselem et al., "Laron Dwarfism and Mutations of the Growth Hormone-Receptor Gene", The New England Journal of Medicine, 321(15):989-995 (1989).
Amselem et al., "Molecular Defects in the Growth Hormone Receptor", Acta Paediatr Scand [Suppl], 377:81-86 (1991).
Attie et al., "Evidence for Partial Growth Hormone (GH) Insensitivity among Idiopathic Short Stature (ISS) Patients Treated with growth Hormone", 4th Joint LWPES/ESPE Meeting San Francisco (1993).
Backeijauw et al., "Effects of Prolonged IGF-I Treatment in Children with Growth Hormone Insensitivity Syndrome (GHIS)", Pediatr. Res., 33:S56, 5 Suppl., #314 (1993).
Baumann et al., "Absence of the Plasma Growth Hormone-Binding Protein in Laron-Type Dwarfism", Journal of Clinical Endocrionology and Metabolism, 65(4):814-816 (1987).
Baumann et al., "Circulating Molecular Varients of Growth Hormone in Childhood", Pediatric Research, 22(1):21-22 (1987).
Baumann et al., "Short Stature and Decreased Serum Growth Hormone-Binding Protein in the Mountain Ok People of Papua New Guinea", Journal of Clinical Endocrionology and Metabolism, 72(6):1346-1349 (1991).
Baumbach et al., "The Growth Hormone-Binding Protein in Rat Serum is an Alternatively Spliced Form of the Rat Growth Hormone Receptor", Genes & Development, 3:1199-1205 (1989).
Bierich et al., "Die Spontansekretion des Wachstumshormons bei der konstittionellen Entwicklungsverzogerung und der froohnormalen Pubertat", Monatsschritt fur Kinderheilkunde, 127:561-565 (1979).
Blum et al., "Growth Hormone Insensitivity Syndromes: A Preliminary Report On Charges in Insulin-Like Growth Factors and Their Binding Proteins During Treatment with Recombinant Insulin-Like Factor I", Acta Paediatr Suppl, 391:15-19 (1993).
Blum et al., "Clinical Studies of IGFBP-2 by Radioimmunoassay", Growth Regulations, 3:100-104 (1993).
Bramswig et al., "Adult Height in Boys and Girls with Untreated Short Stature and Constitutional Delay of Growth-And Puberty: Accuracy of Five Different Methods of Height Prediction", The Journal of Pediatrics, 117:886-891 (1990).
Buchanan et al., "Laron-Type Dwarfism with Apparently Normal High Affinity Serum Growth Hormone-Binding Protein", Clinical Endocrinology, 35:179-185 (1991).
Carlsson et al., "Analysis of 24-Hour Plasma Profiles of Growth Hormone (GH)-Binding Protein, GH/GH-Binding Protein-Complex
Attie Kenneth
Carlsson Lena Mariana Susann
Gesundheit Neil
Goddard Audrey
Genentech Inc.
Hasak Janet E.
Schain Howard E.
Touzeau Lynn
LandOfFree
Treatment of partial growth hormone insensitivity syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of partial growth hormone insensitivity syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of partial growth hormone insensitivity syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2408858